Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Numerate, Boehringer ink research collaboration deal
The collaboration will make use of Numerate’s silico drug design technology to develop novel small molecule drug leads for an undisclosed infectious disease target. Numerate’s drug design platform
The collaboration will make use of Numerate’s silico drug design technology to develop novel small molecule drug leads for an undisclosed infectious disease target. Numerate’s drug design platform
The new supplements range includes Altrient C and Altrient ME with Altrient GSH, which will hit the stores in early 2012. Altrient C is a vitamin C formula,
The completion of preclinical development activities have triggered the milestone. GenVec entered into a worldwide licensing and collaboration agreement with Novartis in January 2010 to discover and develop
The 47,000m² of the facility will take charge of drug discovery, translational research, clinical development, regulatory affairs and external scientific research programs. The first phase of construction is
Afectair is a series of proprietary ventilator circuit patient interface connectors, that eases the delivery of any inhaled therapies to critical care patients requiring ventilatory support. The in-vitro
Caduet is a fixed-dose combination of Atorvastatin-Amlodipine besylate indicated for patients suffering from both, high blood pressure and high levels of cholesterol. Ranbaxy Americas senior vice-president and regional
The Anapen 500mcg, produced by Lincoln Medical, is an epinephrine auto-injector used in the treatment of allergic reactions such as anaphylaxis. The Resuscitation Council of UK has recommended
Galvus (vildagliptin) is a DPP-4 inhibitor that blocks the breakdown of incretin hormones in the body that stimulate the pancreas to produce insulin. The approval is backed by
Bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody, acts by targeting PS and thereby enabling the immune system to recognise and fight the tumor. The randomised Phase II lung cancer
According to Acetylon, Sidera proved to be a suitable choice to meet its growing data needs owing to Sidera’s reliable and secure communications network and Internet Access Service.